Collectively, blocking CD38 receptor function with AT-1 selectively diminished CLL proliferation and pSyk activation along with CD45activtyhi CLL populations, CD43, galectin-1, and CD38 expression, while DARA broadly targeted CD38+ cells. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.